Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12575MR)

This product GTTS-WQ12575MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Felinized
RefSeq XM_004001117.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100144611
UniProt ID A0A337SBN0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ12575MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8205MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ6950MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ14416MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ10227MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ15133MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SYNT-001
GTTS-WQ12190MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ5414MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ11953MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLTA3698A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW